Efficacy and safety of Bruton's tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma patients:a meta-analysis
Objective To systematically evaluate the efficacy and safety of Bruton's tyrosine kinase(BTK)inhibitors(acalabrutinib,zanubrutinib,and ibrutinib and orelabrutinib)in relapsed/refractory mantle cell lymphoma(R/R MCL)and provide a reference for clinical therapy.Methods According to the Cochrane manual,five databases including Embase,Cochrane Library,CNKI,Wanfang,and Medline database were searched from January 2010 to February 2023.The literatures were screened according to the inclusion and exclusion criteria,basic data were extracted,and the quality of included literature was evaluated.RevMan5.4 and R 4.0.5 software were used for meta-analysis.Results Nine studies were included in the meta-analysis.Meta-analysis showed that the CRR comparison was highest in the ibrutinib combined with the rituximab group.According to safety outcomes,the combination treatment group was associated with a higher incidence of diarrhea,nausea,and fatigue.Conclusion BTK inhibitors have significant anti-tumor activity and good safety in R/R MCL patients.
万方数据
维普
